Singapore markets closed

Kyowa Kirin Co., Ltd. (KYKOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
21.580.00 (0.00%)
At close: 12:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.58
Open21.53
Bid0.00 x 0
Ask0.00 x 0
Day's range21.58 - 21.58
52-week range21.22 - 36.25
Volume87
Avg. volume680
Market cap11.596B
Beta (5Y monthly)0.35
PE ratio (TTM)28.25
EPS (TTM)0.76
Earnings dateN/A
Forward dividend & yield0.42 (1.93%)
Ex-dividend date29 Jun 2022
1y target estN/A
  • Business Wire

    MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress

    SAN DIEGO & TOKYO, June 10, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered

  • Business Wire

    MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

    SAN DIEGO & TOKYO, June 04, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta

  • Business Wire

    MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022

    SAN DIEGO & TOKYO, May 26, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an investigational phosphatidylinosit